Overview

Atorvastatin as Adjunctive Therapy in COVID-19

Status:
Recruiting

Trial end date:
2022-05-08

Target enrollment:
0

Participant gender:
All

Summary

Objective: To assess whether adjunctive therapy of COVID-19 infection with atorvastatin reduces the deterioration in hospitalized patients and improves clinical outcome.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Mount Auburn Hospital

Treatments:

Atorvastatin

Criteria

Inclusion Criteria:

- Patient aged 18-85 years, admitted with suspected COVID-19 disease based on clinical
criteria (typical upper respiratory symptoms, e.g. runny nose, sore throat, dry cough,
associated with COVID-19 infection).

Exclusion Criteria:

- already on chronic statin therapy, known hypersensitivity or adverse events to
statins, negative nasopharyngeal (NP) swab for SARS-CoV-2, pregnancy and lactation,
need for ICU admission, ALT or AST >2X upper limit of normal; CPK > 5x upper limit of
normal; and creatinine clearance <50%, chronic treatment with colchicine, cyclosporin,
digoxin, fusidic acid, azole antifungals, niacin.